FDA chief's office said it wants to cut the filing review from 60 days to one week The office said it may cut those reviews to two or three weeks based on complexity The agency could decide on Lilly's ...

Top officials at the U.S. FDA have internally urged its reviewers to speed up the evaluation of Eli Lilly’s (LLY) marketing application for its weight loss pill orforglipron after the Indiana-based ...

LOS ANGELES (KABC) -- This might sound familiar: Chevrolet is coming out with a new electric car called the Bolt. Okay, technically they're bringing back the Bolt for 2027, after it was dropped a ...

To watch “Hamnet” or not to watch “Hamnet,” that is the question. Luckily, the answer is simple: a clear and resounding yes. “Hamnet,” which debuted in select theaters Nov. 26, has been advertised as ...

We may receive a commission on purchases made from links. When seized bolts get in the way of finishing a repair job, the right penetrating oil can be the difference between wrapping up a task in ...

The Toronto Blue Jays fell one game short of a World Series title, and they didn't waste any time improving their roster this offseason. Weeks after losing Game 7 of the World Series, the Blue Jays ...

Questions surround their effects on brain health, pregnancy or long-term use. MIT Technology Review Explains: Let our writers untangle the complex, messy world of technology to help you understand ...

The Toronto Blue Jays were within one game and one run of winning the World Series this season, but they ultimately came up short to the Los Angeles Dodgers. Now, the Blue Jays are at risk of losing ...

The revised 2027 Chevrolet Bolt returns with better range, an improved interior, faster charging and a budget-friendly price. However, a lack of one popular feature may keep it from greatness. We all ...

GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term safety, side effects, and global accessibility. Researchers stress ...

As an editor and writer who has contributed to many national and local publications, Nicole Gregory enjoys communicating clearly on critical health topics so that readers can make informed choices for ...

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks Consensus Estimate of a loss of $5.07. This compares to a loss of $8 per share a year ago. These ...